🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are increasing globally, with data suggesting over 82 million instances per year. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, escalating drug resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Testing Outcomes and Global Access

Based on findings detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which combines an injection and a pill. The trial enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Clinicians treating patients have voiced positive views. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.